Jane Henderson, Chief Financial Officer at Apogee Therapeutics, Inc. (APGE), sold 2,000 shares at $69.43 ($140K) on 2026-03-02, disclosed to the SEC on 2026-03-04.
Scheduled sale ($140k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.27 | 300 | $20K | 14.6% |
| 2 | $69.43 | 300 | $21K | 14.8% |
| 3 | $70.45 | 994 | $70K | 49.9% |
| 4 | $71.66 | 406 | $29K | 20.7% |
| Total | $70.22 avg | 2,000 | $140K | 100% |
| Filing → |
| APGE | SELL | 2026-04-03 | $170K | — | Filing → |
| APGE | SELL | 2026-03-27 | $170K | — | Filing → |
| APGE | SELL | 2026-02-04 | $132K | — | Filing → |